Regulus Therapeutics (RGLS) News Today → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free RGLS Stock Alerts $2.42 +0.15 (+6.61%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVivo Capital LLC Acquires New Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)marketbeat.com - April 27 at 9:40 PMRegulus Therapeutics (NASDAQ:RGLS) Shares Cross Above 200-Day Moving Average of $1.61americanbankingnews.com - April 24 at 3:44 AMRegulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKDseekingalpha.com - April 10 at 1:50 PMBuy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment Needsmarkets.businessinsider.com - March 28 at 2:29 PMShort Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 9,244.3%marketbeat.com - March 27 at 10:53 AMBuy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestonesmarkets.businessinsider.com - March 26 at 3:28 AMRegulus Therapeutics (NASDAQ:RGLS) Given "Buy" Rating at HC Wainwrightmarketbeat.com - March 25 at 8:21 AMRegulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancementsfinance.yahoo.com - March 23 at 10:30 AMRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updatesfinanznachrichten.de - March 22 at 7:21 AMRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023investorplace.com - March 21 at 11:00 PMRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updatesfinance.yahoo.com - March 21 at 4:20 PMBuy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment Datamarkets.businessinsider.com - March 19 at 11:39 PMRGLS Mar 2024 7.500 putfinance.yahoo.com - March 15 at 5:16 AMBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & Morefinance.yahoo.com - March 14 at 2:15 PMRegulus’s Stock RGLS: Hold Rating Amidst Promising Yet Preliminary ADPKD Study Results and Financial Positionmarkets.businessinsider.com - March 13 at 2:40 PMRegulus Therapeutics Shares Soar on Funding, Study Datamarketwatch.com - March 12 at 7:11 PMRegulus Surges 60% On Positive Outcome From Phase1b MAD Trial, Private Placement Of $100 Mlnmarkets.businessinsider.com - March 12 at 2:10 PMWhy Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?msn.com - March 12 at 2:10 PMmarketbeat.com - March 12 at 11:24 AMConsumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bellmsn.com - March 12 at 9:10 AMRegulus Announces $100 Mln Private Placement, Positive Data From Phase 1b MAD Trial Of RGLS8429markets.businessinsider.com - March 12 at 9:10 AMRegulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equityprnewswire.com - March 12 at 6:32 AMRegulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)prnewswire.com - March 12 at 6:30 AMRegulus Therapeutics Incmoney.usnews.com - February 16 at 5:33 PMRegulus concludes enrolment in Phase I trial’s third cohort for ADPKDmsn.com - January 3 at 2:56 PMRegulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)finance.yahoo.com - January 2 at 5:49 PMRegulus Therapeutics files for $150M mixed shelfseekingalpha.com - December 27 at 5:14 PMRegulus Therapeutics Inc RGLSmorningstar.com - December 23 at 12:14 AMRegulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conferencefinance.yahoo.com - November 22 at 12:57 PMRegulus Stock Maintains Buy Rating Amid Financial Stability and Positive Clinical Trial Progressmarkets.businessinsider.com - November 11 at 9:41 AMRegulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updatesfinance.yahoo.com - November 9 at 7:31 PMRegulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)finance.yahoo.com - November 2 at 12:25 PMRegulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)finance.yahoo.com - October 19 at 1:24 PMRegulus Therapeutics (RGLS) Price Target Increased by 13.64% to 6.38nasdaq.com - October 5 at 8:41 AMCanaccord Genuity Maintains Regulus Therapeutics (RGLS) Buy Recommendationmsn.com - September 22 at 2:13 PMAnalyst Expectations for Regulus Therapeutics's Futuremarkets.businessinsider.com - September 21 at 2:01 PMRegulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney Diseasemsn.com - September 20 at 3:55 PMRegulus Reports Positive Topline Data From First Cohort Of Patients In Phase 1b Study Of RGLS8429markets.businessinsider.com - September 20 at 9:41 AMRegulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)finance.yahoo.com - September 20 at 9:41 AMRegulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)finance.yahoo.com - September 13 at 9:46 AMRegulus Therapeutics Announces Participation at Two Healthcare Investment Conferencesfinance.yahoo.com - September 5 at 5:04 PMRegulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?gurufocus.com - August 24 at 9:01 PMRegulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformancefinance.yahoo.com - August 23 at 5:38 PMRegulus Therapeutics to Host Virtual Investor Event on September 6, 2023finance.yahoo.com - August 23 at 8:35 AMRegulus (RGLS) Gets a Buy from H.C. Wainwrightmarkets.businessinsider.com - August 9 at 3:48 PMRegulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updatesfinance.yahoo.com - August 8 at 9:15 PMRegulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conferencefinance.yahoo.com - August 2 at 12:38 PMRegulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conferencefinance.yahoo.com - July 18 at 1:04 PMExpert Ratings for Regulus Therapeuticsmarkets.businessinsider.com - June 28 at 1:59 PMH.C. Wainwright Remains a Buy on Regulus (RGLS)markets.businessinsider.com - June 28 at 8:59 AM Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address His win rate puts Warren Buffett to shame… (Ad)Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss. Click here now for the full story. RGLS Media Mentions By Week RGLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGLS News Sentiment▼1.130.33▲Average Medical News Sentiment RGLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGLS Articles This Week▼21▲RGLS Articles Average Week Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Rigel Pharmaceuticals News Emergent BioSolutions News Vanda Pharmaceuticals News Verastem News XOMA News Bolt Biotherapeutics News Lexicon Pharmaceuticals News scPharmaceuticals News Renovaro News Skye Bioscience News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGLS) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
